Navigation Links
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Date:2/1/2010

CAMBRIDGE, Mass., Feb. 1 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study in 2010.

"We are pleased that the FDA approved the SPA agreement and are confident that we now have a clearly defined path to submission of a Biologics License Application for Vascugel," said Fred Chereau, president and chief executive officer at Pervasis. "We look forward to beginning the Phase 3 study and to confirming the safety and efficacy results from our Phase 1/2 study in a larger patient population."  

This Phase 3, single-blind, randomized, controlled, multi-center study will evaluate the efficacy and safety of Vascugel in approximately 390 patients with end-stage renal disease (ESRD) undergoing creation of an arteriovenous (AV) graft for hemodialysis access. The primary objective of this study will be to evaluate the efficacy of Vascugel in extending the duration of primary patency (lack of vessel obstruction) as compared to standard-of-care treatment.  

Under the SPA procedure, FDA formalizes its agreement that the design of the Phase 3 trial is acceptable to support a regulatory submission seeking new drug approval.

The SPA agreement follows the recent publication of positive Phase 1/2 results for Vascugel in the December issue of the Journal of Vascular Surgery (Conte et al. J Vasc Surg 2009; 50:1359-68). The study was designed to assess feasibility, safety, and preliminary effects on patency of Vascugel in patients requiring
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Pomerantz Grossman ... claims on behalf of investors of Intuitive Surgical, Inc. ... ) (CUSIP: 46120E602) who purchased Intuitive Surgical common stock ... "Class Period"). Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation ...
(Date:5/22/2013)... 2013 Hemoglobin A1C levels increased over ... 2 diabetes, while modest improvements in A1C control ... can lead to substantial healthcare cost savings, according ... for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual ... by Valeritas, makers of the V-Go ® ...
(Date:5/22/2013)... 2013 Ranbaxy Laboratories Limited (hereafter, Ranbaxy), ... Daiichi Sankyo), announced on May 22 the actions ... address past conduct under prior management ... Sankyo continues to support Ranbaxy in its efforts ... past which led to the investigations by the ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... YORK, Dec 1, 2011 Reportlinker.com announces that a new ... The Outlook for Medical Devices in Latin America ... Covered! Argentina Brazil ... Cuba Mexico Peru ...
... Fla., Dec. 1, 2011  Hybrid Fuels, Inc. (Pink Sheets: ... acquired 100% of the shares of EMG Marketing Solutions, ... sales, marketing and product development expertise to the multi-billion ... a wholly owned subsidiary of Hybrid Fuels. ...
Cached Medicine Technology:The Outlook for Medical Devices in Latin America 2The Outlook for Medical Devices in Latin America 3The Outlook for Medical Devices in Latin America 4Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry 2
(Date:5/22/2013)... Troy, NY (PRWEB) May 22, 2013 ... Sinai and Rensselaer Polytechnic Institute today announced an ... and development of new diagnostic tools and treatments ... in a signing ceremony on May 22, 2013. ... their expertise—Rensselaer’s in engineering and invention prototyping and ...
(Date:5/22/2013)... (HealthDay News) -- Children and teens exposed to radiation ... develop cancer, according to a large, long-term study. ... of 10,000 young people who each had one CT ... to occur within 10 years, according to researchers from ... carefully weight the risks to patients when making decisions ...
(Date:5/22/2013)... MA -- A typical pair of running shoes generates ... a 100-watt light bulb on for one week, according ... surprising to researchers isn,t the size of a shoe,s ... comes from. , The researchers found that more than ... from manufacturing processes, with a smaller percentage arising from ...
(Date:5/22/2013)... CORVALLIS, Ore. Researchers have developed a new drug ... help treat lung cancer, and in laboratory and animal ... to other organs while significantly improving the treatment of ... extraordinarily small size of nanoparticles, existing cancer drugs, and ... of cancer cells to resist attack. , The combination ...
(Date:5/22/2013)... TheBeautyPlace.com features Toppik and Bosley hair fibers, two hair loss ... or balding hair. Hair loss treatments can be a lengthy ... during this waiting period, one can use these hair loss ... hair transplant surgery in general. , Bosley and Toppik ... way to eliminate the appearance of balding and thinning hair. ...
Breaking Medicine News(10 mins):Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 3Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 4Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 5Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 6Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 7Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:Footwear's (carbon) footprint 2Health News:Footwear's (carbon) footprint 3Health News:Footwear's (carbon) footprint 4Health News:Research offers promising new approach to treatment of lung cancer 2Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2
... Nevada,s,largest and most trusted medical imaging company celebrates ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050322/DRLOGO ) On ... in Desert,Radiologists and Las Vegas history by completing ... to the people of Southern,Nevada and beyond. ...
... WASHINGTON, Aug. 30 HHS Secretary Mike,Leavitt today ... $75,million to states, territories and four metropolitan areas ... pandemic influenza outbreak., "The additional funding will ... to continue planning, training and acquiring needed equipment,for ...
... The following was issued,today by Active Minds, Inc.: ... Active Minds, Inc. WHAT: Ms. Malmon is available ... including depression and suicide Ms. Malmon is a ... for her unique peer-to-peer approach in addressing,the mental health ...
... Received Compassionate Hospice Care Before Dying, Thailand,s Lop Buri ... Partner to Open, Free AIDS Treatment Center Providing Lifesaving Antiretroviral ... Ceremony Friday, ... August 31st at 9:30 am, LOP ...
... Honberg,director of policy and legal affairs for the National ... today,s Virginia Tech,Panel Report: "The report is important ... just in Virginia but throughout the country. Last ... in,a national survey. The national average also was ,D., ...
... ATSI ), manufacturer and marketer of state-of-the-art ... will present at the,2007 Thomas Weisel Partners Healthcare ... Company,s presentation is scheduled for Wednesday, September,5, 2007 ... and CEO of ATS,Medical, will present a review ...
Cached Medicine News:Health News:Dr. Paul Bandt Celebrates 35th Anniversary With Desert Radiologists and a History of Healthcare in Las Vegas 2Health News:Dr. Paul Bandt Celebrates 35th Anniversary With Desert Radiologists and a History of Healthcare in Las Vegas 3Health News:HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness 2Health News:College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues 2Health News:Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri 2Health News:Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri 3Health News:Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri 4Health News:Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri 5Health News:Virginia Tech Report Has National Importance 2Health News:ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
ELISA kit for Varicella-zoster IgM....
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay ... quantitative determination of IgG antibody to VZV ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
... Zeus Scientific, Inc. Mumps IgG ELISA test ... of Mumps IgG antibody in human serum. ... results of this test, together with other ... of immune status, and/or aid in the ...
Medicine Products: